370 related articles for article (PubMed ID: 16770292)
41. MAO-B inhibitors in Parkinson's disease.
Olanow CW
Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
[No Abstract] [Full Text] [Related]
42. Neuroprotection by selegiline and other MAO inhibitors.
Stern G
J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613
[TBL] [Abstract][Full Text] [Related]
43. MAO inhibitors: risks, benefits, and lore.
Wimbiscus M; Kostenko O; Malone D
Cleve Clin J Med; 2010 Dec; 77(12):859-82. PubMed ID: 21147941
[TBL] [Abstract][Full Text] [Related]
44. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
Olanow CW; Myllylä VV; Sotaniemi KA; Larsen JP; Pålhagen S; Przuntek H; Heinonen EH; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne UK
Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034
[TBL] [Abstract][Full Text] [Related]
45. Clinical trials of neuroprotection for Parkinson's disease.
LeWitt PA
Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583
[No Abstract] [Full Text] [Related]
46. Deprenyl--past and future. Proceedings of a symposium. Lake Starnberg, Bavaria, 1995.
J Neural Transm Suppl; 1996; 48():1-112. PubMed ID: 9102455
[No Abstract] [Full Text] [Related]
47. Deprenyl's neuroprotective action remains unresolved.
van Hilten JJ; Bloem BR; Klaassen AA
Ann Neurol; 1996 Aug; 40(2):266-7. PubMed ID: 8773615
[No Abstract] [Full Text] [Related]
48. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
Marconi S; Zwingers T
Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1879-82. PubMed ID: 25010617
[TBL] [Abstract][Full Text] [Related]
49. Neuroprotection for Parkinson's disease: prospects and promises.
Olanow CW; Schapira AH; Agid Y
Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093
[No Abstract] [Full Text] [Related]
50. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].
Oberpichler-Schwenk H
Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119
[No Abstract] [Full Text] [Related]
51. Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.
Thase ME
J Clin Psychiatry; 2006 Apr; 67(4):671-2. PubMed ID: 16669733
[No Abstract] [Full Text] [Related]
52. Transdermal selegiline: the new generation of monoamine oxidase inhibitors.
Patkar AA; Pae CU; Masand PS
CNS Spectr; 2006 May; 11(5):363-75. PubMed ID: 16641841
[TBL] [Abstract][Full Text] [Related]
53. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
54. Mortality associated with selegiline in Parkinson's disease. What do the available data mean?
Mizuno Y; Kondo T
Drug Saf; 1997 May; 16(5):289-94. PubMed ID: 9187529
[TBL] [Abstract][Full Text] [Related]
55. Selegiline-transdermal--Somerset: Emsam.
Drugs R D; 2003; 4(1):59-60. PubMed ID: 12568641
[No Abstract] [Full Text] [Related]
56. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
57. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O
BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764
[No Abstract] [Full Text] [Related]
58. Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS).
Jang S; Jung S; Pae C; Kimberly BP; Craig Nelson J; Patkar AA
J Affect Disord; 2013 Dec; 151(3):854-9. PubMed ID: 24021959
[TBL] [Abstract][Full Text] [Related]
59. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Jenner P
Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581
[No Abstract] [Full Text] [Related]
60. Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.
Breteler MM
BMJ; 1998 Apr; 316(7139):1182-3. PubMed ID: 9552992
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]